AL002 for Alzheimer's Disease

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Alzheimer's DiseaseAL002 - Drug
Eligibility
50 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new drug, AL002, is effective and safe in people with early Alzheimer's disease.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Through study completion, up to 48 through 96 weeks

Week 96
Change in ADAS-Cog13 score
Change in ADCOMS score
Change in ADCS-ADL-MCI score
Change in CSF biomarkers (optional)
Change in MMSE score
Change in RBANS score
Change in Winterlight Language Speech Assessment score (optional)
Change in amyloid burden as assessed by positron emission tomography imaging (optional)
Change in blood based biomarkers
Change in brain volume as assessed by magnetic resonance imaging
Change in tau tangles as assessed by positron emission tomography imaging (optional)
Disease progression as measured by the CDR-SB
Evaluation of safety and tolerability of AL002: Incidence of adverse events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Trial Design

4 Treatment Groups

AL002 Dose 1
1 of 4
AL002 Dose 2
1 of 4
AL002 Dose 3
1 of 4
Placebo
1 of 4

Experimental Treatment

Non-Treatment Group

265 Total Participants · 4 Treatment Groups

Primary Treatment: AL002 · Has Placebo Group · Phase 2

AL002 Dose 1
Drug
Experimental Group · 1 Intervention: AL002 · Intervention Types: Drug
AL002 Dose 2
Drug
Experimental Group · 1 Intervention: AL002 · Intervention Types: Drug
AL002 Dose 3
Drug
Experimental Group · 1 Intervention: AL002 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AL002
2018
Completed Phase 1
~70

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 48 through 96 weeks

Who is running the clinical trial?

Alector Inc.Lead Sponsor
7 Previous Clinical Trials
540 Total Patients Enrolled
AbbVieIndustry Sponsor
835 Previous Clinical Trials
471,055 Total Patients Enrolled
TBD TBDPrincipal Investigator
3 Previous Clinical Trials
224 Total Patients Enrolled

Eligibility Criteria

Age 50 - 85 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of early Alzheimer's disease, including evidence of brain amyloidosis by CSF or PET.
You must be of legal age to consent to participate in this study.
You have a MMSE score of 22 or higher, a CDR Global Score of 0.5 - 1.